These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 8882314

  • 1. Efficacy of an inactivated feline leukemia virus vaccine.
    Hoover EA, Mullins JI, Chu HJ, Wasmoen TL.
    AIDS Res Hum Retroviruses; 1996 Mar 20; 12(5):379-83. PubMed ID: 8882314
    [Abstract] [Full Text] [Related]

  • 2. Development and testing of an inactivated feline leukemia virus vaccine.
    Hoover EA, Mullins JI, Chu HJ, Wasmoen TL.
    Semin Vet Med Surg Small Anim; 1995 Nov 20; 10(4):238-43. PubMed ID: 8820598
    [Abstract] [Full Text] [Related]

  • 3. Protection against feline leukemia virus infection by use of an inactivated virus vaccine.
    Hoover EA, Perigo NA, Quackenbush SL, Mathiason-DuBard CK, Overbaugh JM, Kloetzer WS, Elder JH, Mullins JI.
    J Am Vet Med Assoc; 1991 Nov 15; 199(10):1392-401. PubMed ID: 1666090
    [Abstract] [Full Text] [Related]

  • 4. Comparative Efficacy of Feline Leukemia Virus (FeLV) Inactivated Whole-Virus Vaccine and Canarypox Virus-Vectored Vaccine during Virulent FeLV Challenge and Immunosuppression.
    Patel M, Carritt K, Lane J, Jayappa H, Stahl M, Bourgeois M.
    Clin Vaccine Immunol; 2015 Jul 15; 22(7):798-805. PubMed ID: 25972402
    [Abstract] [Full Text] [Related]

  • 5. Protection against feline leukemia virus challenge for at least 2 years after vaccination with an inactivated feline leukemia virus vaccine.
    Jirjis FF, Davis T, Lane J, Carritt K, Sweeney D, Williams J, Wasmoen T.
    Vet Ther; 2010 Jul 15; 11(2):E1-6. PubMed ID: 20957616
    [Abstract] [Full Text] [Related]

  • 6. Feline leukemia virus immunity induced by whole inactivated virus vaccination.
    Torres AN, O'Halloran KP, Larson LJ, Schultz RD, Hoover EA.
    Vet Immunol Immunopathol; 2010 Mar 15; 134(1-2):122-31. PubMed ID: 20004483
    [Abstract] [Full Text] [Related]

  • 7. Anti-SU Antibody Responses in Client-Owned Cats Following Vaccination against Feline Leukaemia Virus with Two Inactivated Whole-Virus Vaccines (Fel-O-Vax® Lv-K and Fel-O-Vax® 5).
    Westman M, Norris J, Malik R, Hofmann-Lehmann R, Parr YA, Armstrong E, McDonald M, Hall E, Sheehy P, Hosie MJ.
    Viruses; 2021 Feb 03; 13(2):. PubMed ID: 33546485
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of an inactivated FeLV vaccine compared to a recombinant FeLV vaccine in minimum age cats following virulent FeLV challenge.
    Stuke K, King V, Southwick K, Stoeva MI, Thomas A, Winkler MT.
    Vaccine; 2014 May 07; 32(22):2599-603. PubMed ID: 24662705
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of a feline leukemia virus vaccine in a controlled natural transmission study.
    Lafrado LJ.
    J Am Vet Med Assoc; 1994 Mar 15; 204(6):914-7. PubMed ID: 8188511
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of efficacy and safety of an inactivated virus vaccine against feline leukemia virus infection.
    Hines DL, Cutting JA, Dietrich DL, Walsh JA.
    J Am Vet Med Assoc; 1991 Nov 15; 199(10):1428-30. PubMed ID: 1666097
    [Abstract] [Full Text] [Related]

  • 11. Protection from challenge following administration of a canarypox virus-vectored recombinant feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine.
    Grosenbaugh DA, Leard T, Pardo MC.
    J Am Vet Med Assoc; 2006 Mar 01; 228(5):726-7. PubMed ID: 16506935
    [Abstract] [Full Text] [Related]

  • 12. Induction of protective immune response in cats by vaccination with feline leukemia virus iscom.
    Osterhaus A, Weijer K, Uytdehaag F, Jarrett O, Sundquist B, Morein B.
    J Immunol; 1985 Jul 01; 135(1):591-6. PubMed ID: 2987351
    [Abstract] [Full Text] [Related]

  • 13. Vaccination of cats experimentally infected with feline immunodeficiency virus, using a recombinant feline leukemia virus vaccine.
    Lehmann R, Franchini M, Aubert A, Wolfensberger C, Cronier J, Lutz H.
    J Am Vet Med Assoc; 1991 Nov 15; 199(10):1446-52. PubMed ID: 1666101
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the safety and efficacy of a recombinant feline leukemia virus (FeLV) vaccine delivered transdermally and an inactivated FeLV vaccine delivered subcutaneously.
    Grosenbaugh DA, Leard T, Pardo MC, Motes-Kreimeyer L, Royston M.
    Vet Ther; 2004 Nov 15; 5(4):258-62. PubMed ID: 15719325
    [Abstract] [Full Text] [Related]

  • 15. Immunization with the transmembrane protein of a retrovirus, feline leukemia virus: absence of antigenemia following challenge.
    Langhammer S, Hübner J, Jarrett O, Kurth R, Denner J.
    Antiviral Res; 2011 Jan 15; 89(1):119-23. PubMed ID: 21108970
    [Abstract] [Full Text] [Related]

  • 16. Protection against oronasal challenge with virulent feline leukaemia virus lasts for at least 12 months following a primary course of immunisation with Leukocell 2 vaccine.
    Harbour DA, Gunn-Moore DA, Gruffydd-Jones TJ, Caney SM, Bradshaw J, Jarrett O, Wiseman A.
    Vaccine; 2002 Jul 26; 20(23-24):2866-72. PubMed ID: 12126896
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy of a nonadjuvanted recombinant FeLV vaccine and two inactivated FeLV vaccines when subject to consistent virulent FeLV challenge conditions.
    Grosenbaugh DA, Frances-Duvert V, Abedi S, Feilmeier B, Ru H, Poulet H.
    Biologicals; 2017 Sep 26; 49():76-80. PubMed ID: 28734742
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy studies of live- and killed-feline leukemia virus vaccines.
    Pedersen NC, Theilen GH, Werner LL.
    Am J Vet Res; 1979 Aug 26; 40(8):1120-6. PubMed ID: 230767
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.